The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation

Immunological Reviews

Volumn 172, Issue , 1999, Pages 121-129

  Nakagawa, Terry Y ^a   Rudensky, Alexander Y ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN E; CATHEPSIN L; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEINASE;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; EPITHELIUM CELL; IMMUNE RESPONSE; LYSOSOME; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE; THYMOCYTE;

EID: 0033430264     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01361.x     Document Type: Article

References (68)

1. 1. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 1992;10:13-49.
2. 2. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 1995;11:267-306.
3. 3. Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci USA 1991;88:3150-3154.
4. 4. Anderson MS, Miller J. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1992;89:2282-2286.
5. 5. Lamb CA, Yewdell JW, Bennink JR, Cresswell P. Invariant chain targets HLA class II molecules to acidic endosomes containing internalized influenza virus. Proc Natl Acad Sci USA 1991;88:5998-6002.
6. 6. Fineschi B, Arneson LS, Naujokas MF, Miller J. Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Proc Natl Acad Sci USA 1995;92:10257-10261.
7. 7. Sant AJ, Miller J. MHC class II antigen processing: biology of invariant chain. Curr Opin Immunol 1994;6:57-63.
8. 8. Cresswell P. Invariant chain structure and MHC class II function. Cell 1996;84:505-507.
9. +T cells. Crit Rev Immunol 1996;16:359-379.
10. 10. Arunachalam B, Lamb CA, Cresswell P. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. Int Immunol 1994;6:439-451.
11. 11. Avva RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994;1:763-774.
12. 12. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990;63:707-716.
13. 13. Lotteau V, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348:600-605.
14. 14. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995;82:155-165.
15. 15. Nelson CA, Vidavsky I, Viner NJ, Gross ML, Unanue ER. Ammo-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1997;94:628-633.
16. 16. Mouritsen S, Meldal M, Werdelin O, Hansen AS, Buus S. MHC molecules protect T cell epitopes against proteolytic destruction. J Immunol 1992;149:1987-1993.
17. 17. Deng H, et al. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. J Exp Med 1993;178:1675-1680.
18. 18. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997;378:141-150.
19. 19. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
20. 20. Santamaria I, Velasco G, Pendas AM, Fueyo A, Lopez-Otin C. Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location. J Biol Chem 1998;273:16816-16823.
21. 21. Wex T, Levy B, Wex H, Bromme D. Human cathepsins F and W: a new subgroup of cathepsins. Biochem Biophys Res Commun 1999;259:401-407.
22. + T-lymphocytes. FEBS Lett 1997;405:253-259.
23. 23. Bromme D, Li Z, Barnes M, Mehler E. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry 1999;38:2377-2385.
24. 24. Fineschi B, Miller J. Endosomal proteases and antigen processing. Trends Biochem Sci 1997;22:377-382.
25. 25. Rawlings ND, Barrett AJ. Families of cysteine peptidases. Methods Enzymol 1994;244:461-486.
26. 26. Turk D, Guncar G, Podobnik M, Turk B. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol Chem 1998;379:137-147.
27. 27. Gieselmann V, Pohlmann R, Hasilik A, von Figura K. Biosynthesis and transport of cathepsin D in cultured human fibroblasts. J Cell Biol 1983;97:1-5.
28. 28. Lingeman RG, Joy DS, Sherman MA, Kane SE. Effect of carbohydrate position on lysosomal transport of procathepsin L. Mol Biol Cell 1998;9:1135-1147.
29. 29. Kasper D, Dittmer F, von Figura K, Pohlmann R. Neither type of mannose 6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes. J Cell Biol 1996;134:615-623.
30. 30. Pohlmann R, Boeker MW, von Figura K. The two mannose 6-phosphate receptors transport disunct complements of lysosomal proteins. J Biol Chem 1995;270:27311-27318.
31. 31. Koster A, Saftig P, Matzner U, von Figura K, Peters C, Pohlmann R. Targeted disruption of the M, 46,000 mannose 6-phosphate receptor gene in mice results in misrouting of lysosomal proteins. EMBO J 1993;12:5219-5223.
32. 32. Nishimura Y, Kato K. Intracellular transport and processing of lysosomal cathepsin B. Biochem Biophys Res Commun 1987;148:254-259.
33. 33. Lenarcic B, Bevec T. Thyropins-new structurally related proteinase inhibitors. Biol Chem 1998;379:105-111.
34. 34. Qian F, Frankfater A, Chan SJ, Steiner DF. The structure of the mouse cathepsin B gene and its putative promoter. DNA Cell Biol 1991;10:159-168.
35. 35. Turk B, et al. Acidic pH as a physiological regulator of human cathepsin L activity. Eur J Biochem 1999;259:926-932.
36. 36. Saftig P, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-Κ-deficient mice. Proc Natl Acad Sci USA 1998;95:13453-13458.
37. 37. Gelb BD, Moissoglu K, Zhang J, Martignetti JA, Bromme D, Desnick RJ. Cathepsin K: isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene. Biochem Mol Med 1996;59:200-206.
38. 38. Mason RW, Wilcox D, Wikstrom P, Shaw EN. The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor. Biochem J 1989;257:125-129.
39. 39. Nakagawa TY, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998;280:450-453.
40. 40. Nakagawa TY, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-217.
41. 41. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 1988;85:3975-3979.
42. 42. Maric MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariant-chain processing. Proc Natl Acad Sci USA 1994;91:2171-2175.
43. 43. Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance α β heterodimers in endosomes. EMBO J 1992;11:411-416.
44. 44. Riese RJ, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996;4:357-366.
45. 45. Riese RJ, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998;101:2351-2363.
46. 46. Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 1997;186:549-560.
47. 47. Palmer JT, Rasnick D, Klaus JL, Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995;38:3193-3196.
48. 48. Deussing J, Roth W. Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 1998;95:4516-4521.
49. 49. Van Noort JM, Jacobs MJ. Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine class II MHC molecules. Eur J Immunol 1994;24:2175-2180.
50. 50. Rodriguez GM, Diment S. Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin. Eur J Immunol 1995;25:1823-1827.
51. 51. Mizuochi T, Yee ST, Kasai M, Kakiuchi T, Muno D, Kominami E. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. Immunol Lett 1994;43:189-193.
52. 52. Takahashi H, Cease KB, Berzofsky JA. Identification of proteases that process distinct epitopes on the same protein. J Immunol 1989;142:2221-2229.
53. 53. Katunuma N, Matsunaga Y, Saibara T. Mechanism and regulation of antigen processing by cathepsin B. Adv Enzyme Regul 1994;34:145-158.
54. 54. Saftig P, et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995;14:3599-3608.
55. 55. Bennett K, et al. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur J Immunol 1992;12:1519-1524.
56. 56. Hewitt EW, Treumann A, Morrice N, Tamell PJ, Kay J, Watts C. Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation. J Immunol 1997;159:4693-4699.
57. 57. Sealy L, Mota F, Rayment N, Tatnell P, Kay J, Chain B. Regulation of cathepsin E expression during human B cell differentiation in vitro. Eur J Immunol 1996;26:1838-1843.
58. 58. Solcia E, et al. Cathepsin E in antigen-presenting Langerhans and interdigitating reticulum cells. Its possible role in antigen processing. Eur J Histochem 1993;37:19-26.
59. 59. Thomas DJ, et al. Stabilisation of cathepsin E by ATP. FEBS Lett 1989;243:145-148.
60. 60. Shi GP, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999;10:197-206.
61. 61. Pierre P, Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 1998;93:1135-1145.
62. 62. Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta 1986;45:1363-1374.
63. 63. Bromme D, Rinne R, Kirschke H. Tight-binding inhibition of cathepsin S by cystatins. Biomed Biochim Acta 1991;50:631-635.
64. 64. Van Noort JM, Boon J, Van der Drift AC, Wagenaar JP, Boots AM, Boog CJ. Antigen processing by endosomal proteases determines which sites of sperm-whale myoglobin are eventually recognized by T cells. Eur J Immunol 1991;21:1989-1996.
65. 65. Rodriguez GM, Diment S. Role of cathepsin D in antigen presentation of ovalbumin. J Immunol 1992;149:2894-2898.
66. 66. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 1998;396:695-699.
67. 67. Chen JM, et al. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem 1997;272:8090-8098.
68. 68. Kovats S, et al. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 1998;187:245-251.